A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Umeclidinium/ Vilanterol; Drug: Olodaterol/Tiotropium Bromide

Study type: Observational

Funder types: Industry

Identifiers

NCT03979807

1237-0090

Details and patient eligibility

About

To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).

Enrollment: 11,296 patients

Sex: All

Ages: 1 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria

• Aged <40 years
• Enrolment with medical and pharmacy coverage prior to the cohort entry < 180 days
• Never had COPD diagnosis on the cohort entry date or prior to cohort entry
• A record for dispensed Olodaterol/Tiotropium Bromide delivered with Respimat inhalator or Umeclidinium/Vilanterol delivered with the Ellipta Inhaler during the 180-day baseline prior to cohort entry
• Diagnosis of asthma any time prior to cohort entry
• Diagnosis of lung cancer any time prior to cohort entry
• Diagnosis of lung transplant any time prior to cohort entry

Trial design

11,296 participants in 1 patient group

Subjects with Chronic obstructive pulmonary disease

Treatment:

Drug: Umeclidinium/ Vilanterol

Drug: Olodaterol/Tiotropium Bromide